(Q37867279)

24 August 2017

1 reference

title

Controversies of anticoagulation reversal in life-threatening bleeds (English)

1 reference

24 August 2017

1 reference

Stephen Rolfe

1

1 reference

PubMed ID

21507817

24 August 2017

Stella Papadopoulos

series ordinal

2

1 reference

PubMed ID

21507817

24 August 2017

Katherine P Cabral

series ordinal

3

1 reference

24 August 2017

13 April 2010

1 reference

Journal of Pharmacy Practice

24 August 2017

1 reference

24 August 2017

23

1 reference

24 August 2017

3

1 reference

24 August 2017

217-225

1 reference

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

24 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Coagulation factor concentrates: past, present, and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Predictors of outcome in warfarin-related intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care a

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Warfarin use leads to larger intracerebral hematomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Recombinant factor VIIa for warfarin-associated intracranial bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Recombinant activated factor VII (rFVIIa/NovoSeven) in intractable haemorrhage: use of a clinical scoring system to predict outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Thromboembolic adverse events after use of recombinant human coagulation factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Guidelines on oral anticoagulation (warfarin): third edition--2005 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Clinical experience with the use of clotting factor concentrates in oral anticoagulation reversal

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Urgent reversal of warfarin with prothrombin complex concentrate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Warfarin reversal in anticoagulant-associated intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Emergency reversal of anticoagulation after intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Use of factor IX complex in warfarin-related intracranial hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Effectiveness of Factor IX complex concentrate in reversing warfarin associated coagulopathy for intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

The Reaction Level Scale (RLS85). Manual and guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrat

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Thrombogenicity of prothrombin complex concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010362168

21 January 2018

Identifiers

DOI

10.1177/0897190010362168

1 reference

24 August 2017

1 reference

PubMed ID

21507817